View Older Stories View More Recent Stories

Sep 7, 2017 06:59AM Bristol-Myers Squibb to Announce Results for Third Quarter 2017 on October 26
Sep 7, 2017 06:59AM CheckMate -214 Study Evaluating Opdivo in Combination with Yervoy Stopped Early for Demonstrating Overall Survival Benefit in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carci
Sep 6, 2017 07:00AM Bristol-Myers Squibb Employees Ride Across the U.S. to Raise Money to Support Cancer Research by Stand Up To Cancer
Sep 5, 2017 06:59AM Bristol-Myers Squibb to Take Part in Morgan Stanley Global Health Care Conference
Aug 30, 2017 06:05PM Bristol-Myers Squibb Data at ESMO 2017 Demonstrate Company’s Innovative Research Approach to Treating Cancer from All Angles
Aug 29, 2017 08:40AM Pfizer (PFE) & Bristol-Meyers Squibb (BMY) Report Positive Real-World Data for Eliquis (Apixaban) Compared to Warfrin in Patients Over 65 with NVAF
Aug 29, 2017 08:21AM Bristol-Myers Squibb and Pfizer Alliance Announce Real-World Observational Analysis of the Effectiveness and Safety of Direct Oral Anticoagulants Compared to Warfarin in Elderly Patients with Non-Valv
Aug 28, 2017 04:02PM Bristol-Myers Squibb (BMY), Daiichi Sankyo Announce Pact to Evaluate Opdivo and DS-8201 in HER2-Expressing Breast and Bladder Cancers
Aug 28, 2017 04:01PM Bristol-Myers Squibb and Daiichi Sankyo Announce Research Collaboration to Evaluate Opdivo® (nivolumab) and DS-8201 in HER2-Expressing Breast and Bladder Cancers
Aug 28, 2017 05:42AM Pfizer (PFE) & Bristol-Myers Squibb (BMY) Report Results of Observational Real-World Data Analysis on the Effectiveness and Safety of Eliquis
Aug 28, 2017 05:00AM Bristol-Myers Squibb and Pfizer Present Investigational Eliquis® (apixaban) Data for Patients with Non-Valvular Atrial Fibrillation (NVAF) Undergoing Cardioversion
Aug 28, 2017 02:30AM Bristol-Myers Squibb and Pfizer Present Observational Real-World Data Analysis on the Effectiveness and Safety of Eliquis® (apixaban) Compared to Warfarin in Select High-Risk Patients with Non-Valvul
Aug 18, 2017 07:02AM Bristol-Myers Squibb (BMY), Pfizer (PFE) to Highlight Commitment to Reducing Risk of Stroke Caused by NVAF and Treating DVT/PE at ESC Congress
Aug 18, 2017 06:59AM Bristol-Myers Squibb and Pfizer to Highlight Commitment to Reducing the Risk of Stroke Caused by Non-Valvular Atrial Fibrillation (NVAF) and Treating Deep Vein Thrombosis/Pulmonary Embolism (DVT/PE) a
Aug 15, 2017 04:31PM Bristol-Myers Squibb (BMY) Says CheckMate -214 Combination Study Met Co-primary Endpoint of ORR but PFS Didn't Reach Statistical Significance
Aug 15, 2017 04:30PM Bristol-Myers Squibb Announces Topline Results from CheckMate -214, a Phase 3 Study of Opdivo in Combination with Yervoy in Intermediate and Poor-Risk Patients with Previously Untreated Advanced or Me
Aug 3, 2017 04:01PM Bristol-Myers Squibb (BMY) to Acquire IFM Therapeutics
Aug 3, 2017 04:00PM Bristol-Myers Squibb to Acquire IFM Therapeutics to Strengthen Oncology Pipeline Focus on Innate Immunity
Aug 1, 2017 07:12AM Bristol-Myers Squibb (BMY) Announces FDA Approval for Opdivo in MSI-H or dMMR Metastatic Colorectal Cancer
Aug 1, 2017 06:59AM Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab) in MSI-H or dMMR Metastatic Colorectal Cancer That Has Progressed Following Treatment with a Fluoropyrimidine, Oxaliplatin, and Irinot
Jul 31, 2017 07:00AM Bristol-Myers Squibb (BMY), Clovis Oncology (CLVS) Enter Clinical Collaboration to Evaluate Combination of Opdivo and Rubraca in Phase 2 and Pivotal Phase 3 Clinical Trials in Tumors
Jul 31, 2017 06:59AM Bristol-Myers Squibb and Clovis Oncology Announce a Broad Clinical Collaboration to Evaluate Combination of Opdivo (Nivolumab) and Rubraca® (Rucaparib) in Phase 2 and Pivotal Phase 3 Clinical Trials
Jul 27, 2017 07:35AM Tech, transports drag on Wall Street; Dow hits record
Jul 27, 2017 06:59AM Bristol-Myers Squibb Reports Second Quarter Financial Results
Jul 26, 2017 06:59AM Bristol-Myers Squibb’s ORENCIA® (abatacept) Receives Second European Commission Approval in Less than a Year – New Approval for Treatment of Active Psoriatic Arthritis (PsA)1
Jul 24, 2017 04:16PM Bristol-Myers Squibb (BMY) Says FDA Accepts Applications for Opdivo Four-Week Dosing Schedule Across All Approved Indications
Jul 24, 2017 04:15PM U.S. Food and Drug Administration Accepts Bristol-Myers Squibb’s Applications for Opdivo (nivolumab) Four-Week Dosing Schedule Across All Approved Indications
Jul 24, 2017 07:01AM Bristol-Myers Squibb (BMY) Granted Expanded Approval by FDA of Yervoy (ipilimumab) to Include Pediatric Patients 12 Years & Older with Unresectable or Metastatic Melanoma
Jul 24, 2017 06:59AM U.S. Food and Drug Administration Expands Approval of Yervoy® (ipilimumab) to Include Pediatric Patients 12 Years and Older with Unresectable or Metastatic Melanoma
Jul 10, 2017 08:06AM Bristol-Myers Squibb (BMY) & Exelis (EXEL) Commence Phase 3 Trial of Opdivo in Combination with CABOMETYX or Opdivo & Yervoy in Combination with CABOMETYX
Jul 10, 2017 08:00AM Exelixis and Bristol-Myers Squibb Initiate Phase 3 Trial of Opdivo® in Combination with CABOMETYX™ or Opdivo and Yervoy® in Combination with CABOMETYX, Versus Sunitinib in Previously Untreated Adv
Jul 10, 2017 06:59AM Bristol-Myers Squibb (BMY) Announces FDA Accepts Priority Review Application for Sprycel in Children with Philadelphia Chromosome-Positive CP Chronic Myeloid Leukemia
Jul 10, 2017 06:58AM U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Sprycel (dasatinib) in Children with Philadelphia Chromosome-Positive Chronic Phase Chronic Myelo
Jul 6, 2017 07:30AM Bristol-Myers Squibb’s ORENCIA (abatacept) Receives FDA Approval for Treatment of Active Psoriatic Arthritis (PsA) in Adults
Jul 5, 2017 06:16AM Bristol-Myers Squibb (BMY) Reports Phase 3 Study Evaluating Opdivo in Resected High-Risk Melanoma Patients Meets Primary Endpoint
Jul 5, 2017 06:15AM Phase 3 Study Evaluating the Safety and Efficacy of Adjuvant Opdivo in Resected High-Risk Melanoma Patients Meets Primary Endpoint
Jun 28, 2017 06:59AM Modern Family Star Eric Stonestreet Challenges Americans to Support the Cancer Community and Learn about Immuno-Oncology Research Through Ready. Raise. Rise.
Jun 24, 2017 10:00AM Four-Year Follow-up with Empliciti (elotuzumab) Plus Lenalidomide/Dexamethasone (ELd) in Patients with Advanced Multiple Myeloma Shows Long-term Efficacy in ELOQUENT-2 Trial
Jun 21, 2017 06:59AM Bristol-Myers Squibb Announces the Expiration of its Cash Tender Offer
Jun 20, 2017 03:40PM Bristol-Myers Squibb Announces the Pricing Terms of its Cash Tender Offer For Any and All of Certain of its Outstanding Debt Securities
Jun 16, 2017 07:00AM Bristol-Myers Squibb (BMY) Presents Extended Follow-Up Data Evaluating Opdivo (nivolumab)
Jun 16, 2017 06:58AM Extended Follow-Up Data Evaluating Opdivo (nivolumab) Shows Durable Response in Adult Patients with Relapsed or Progressed Classical Hodgkin Lymphoma
Jun 16, 2017 05:48AM Bristol-Myers Squibb (BMY) Agrees to Sell Manufacturing Facility in Ireland to SK Biotek Co.; Terms Not Disclosed
Jun 16, 2017 04:35AM Bristol-Myers Squibb to Sell Manufacturing Facility in Swords, Ireland to SK Biotek Co., Ltd.
Jun 15, 2017 07:00AM Seattle Genetics (SGEN) and Bristol-Myers Squibb (BMY) Highlight Interim Phase 1/2 Data Evaluating Combination of ADCETRIS (Brentuximab Vedotin) & Opdivo (Nivolumab)
Jun 15, 2017 06:58AM Seattle Genetics and Bristol-Myers Squibb Highlight Interim Phase 1/2 Data Evaluating Combination of ADCETRIS® (Brentuximab Vedotin) and Opdivo® (Nivolumab) in Relapsed Hodgkin Lymphoma at the Inter
Jun 14, 2017 08:40AM Bristol-Myers Squibb Announces Cash Tender Offer For Any and All of Certain of Its Outstanding Debt Securities
Jun 14, 2017 07:01AM Bristol-Myers Squibb (BMY) to Present Research on RA Patients With Highly Active, Progressive Disease at EULAR 2017
Jun 14, 2017 06:59AM Bristol-Myers Squibb To Present New Research Related to the Treatment of Rheumatoid Arthritis Patients With Highly Active, Progressive Disease at the Annual European Congress of Rheumatology (EULAR 2
Jun 13, 2017 04:05PM Bristol-Myers Squibb Announces Dividend
View More Recent Stories View Older Stories